Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.
Christian Buske, MD
Advertisement
Articles by Christian Buske, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
2
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5